Robert J Hoey

Title: The Innovations of Robert J Hoey

Introduction

Robert J Hoey is a notable inventor based in San Diego, CA. He has made significant contributions to the field of biotechnology, particularly in the development of cannabinoid receptor type 1 (CB1) binding proteins. With a total of 2 patents, his work has implications for the treatment and diagnosis of various conditions related to CB1.

Latest Patents

Hoey's latest patents include innovative technologies related to CB1 antibodies. The first patent, titled "Cannabinoid receptor type 1 (CB1) antibodies, encoding nucleic acid molecules thereof and methods of use thereof," provides isolated, engineered, non-naturally occurring CB1 binding proteins, including anti-CB1 antibodies or antigen-binding fragments thereof. These proteins are designed to be useful in the treatment and diagnosis of CB1 mediated conditions, diseases, and disorders. The second patent, "Cannabinoid receptor type 1 (CB1) binding proteins and uses thereof," similarly focuses on isolated, engineered CB1 binding proteins, emphasizing their utility in medical applications.

Career Highlights

Hoey is currently associated with Takeda Pharmaceutical Company Limited, where he continues to advance his research and innovations. His work at Takeda has positioned him as a key player in the biotechnology sector, contributing to the development of therapies that address critical health issues.

Collaborations

Throughout his career, Hoey has collaborated with talented individuals such as Antara Banerjee and Andrea Fanjul. These collaborations have fostered a dynamic research environment, enhancing the potential for groundbreaking discoveries.

Conclusion

Robert J Hoey's contributions to the field of biotechnology, particularly through his patents on CB1 binding proteins, highlight his innovative spirit and dedication to advancing medical science. His work continues to pave the way for new treatments and diagnostic methods, making a significant impact in the healthcare industry.